Megan E Sheehan

US Patent:

20220380352, Dec 1, 2022

Filed:

May 3, 2022

Appl. No.:

17/661909

Inventors:

- Tokyo, JP
Silvia BUONAMICI - Boston, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Belmont MA, US
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong XIAO - Belmont MA, US

International Classification:

C07D 405/12
A61P 35/00
A61K 47/68
A61K 47/60
A61K 9/127
A61K 9/51
A61K 31/365
A61K 31/496
A61K 39/00
A61K 39/395
A61K 45/06
C07D 313/00
C07D 405/06
C07K 16/24
C07K 16/28
C07K 16/30
C07K 16/32
C07K 16/40
C12Q 1/6886
G01N 33/50
G01N 33/574

Abstract:

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

US Patent:

20230062861, Mar 2, 2023

Filed:

Nov 8, 2021

Appl. No.:

17/521666

Inventors:

- Tokyo, JP
Hyelee LEE - Billerica MA, US
Stephanos IOANNIDIS - Natick MA, US
Kiyoyuki OMOTO - Bedford MA, US
Alan ROLFE - Medford MA, US
Xiang LIU - Winchester MA, US
Megan SHEEHAN - Boston MA, US
Paul DRANSFIELD - Arlington MA, US
Andrew COOK - Stow MA, US

International Classification:

C07D 401/14
C07D 405/14
C07D 413/14
C07D 471/04
C07D 471/08
C07D 493/08
C07D 417/14
C07D 491/04
C07D 409/14
C07D 498/08
C07D 498/04
C07D 487/04
C07D 491/10
C07F 5/02

Abstract:

Disclosed herein are novel compounds of Formula (1) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same.

US Patent:

20210299269, Sep 30, 2021

Filed:

May 31, 2019

Appl. No.:

17/059635

Inventors:

- TOKYO, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Tbilisi, GE
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong Xiao - Belmont MA, US

International Classification:

A61K 47/68
C07K 16/32
C07K 16/28
C07K 16/40
A61K 47/60
C07D 405/06
A61P 35/00
G01N 33/50
C07D 313/00
A61K 31/496
A61K 31/365
A61K 39/395
A61K 45/06
A61K 39/00
A61K 9/127
A61K 9/51
C12Q 1/6886
G01N 33/574
C07K 16/30
C07K 16/24

Abstract:

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

US Patent:

20210101888, Apr 8, 2021

Filed:

Nov 30, 2020

Appl. No.:

17/247117

Inventors:

- Tokyo, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Belmont MA, US
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong XIAO - Belmont MA, US

International Classification:

C07D 405/12
A61P 35/00

Abstract:

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.